Parsa Kiai Acquires 4,329 Shares of Medifast (NYSE:MED) Stock

Medifast Inc (NYSE:MED) Director Parsa Kiai purchased 4,329 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was acquired at an average cost of $12.00 per share, for a total transaction of $51,948.00. Following the completion of the acquisition, the director owned 665,517 shares in the company, valued at $7,986,204. This represents a 0.65% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Parsa Kiai also recently made the following trade(s):

• On Thursday, August 20th, Parsa Kiai acquired 43,150 shares of Medifast stock. The shares were bought at an average cost of $11.60 per share, with a total value of $500,540.00.
• On Wednesday, August 19th, Parsa Kiai acquired 29,337 shares of Medifast stock. The shares were bought at an average price of $11.66 per share, for a total transaction of $342,069.42.

Medifast Stock Performance

Shares of Medifast stock traded up $0.15 on Wednesday, hitting $12.31. 68,380 shares of the company traded hands, compared to its average volume of 229,628. Medifast Inc has a 52 week low of $9.22 and a 52 week high of $14.67. The business has a 50-day simple moving average of $10.94 and a 200 day simple moving average of $11.07. The stock has a market capitalization of $137.68 million, a P/E ratio of -5.30 and a beta of 0.65.

Medifast (NYSE:MED) last issued its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. The firm had revenue of $76.38 million during the quarter, compared to analyst estimates of $72.70 million. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Research analysts expect that Medifast Inc will post -1 earnings per share for the current year.

Hedge Funds Weigh In On Medifast

Several institutional investors have recently bought and sold shares of MED. BlackRock Inc. purchased a new stake in shares of Medifast in the second quarter valued at $3,920,000. Lido Advisors LLC purchased a new position in Medifast during the 3rd quarter worth $4,521,000. Steamboat Capital Partners LLC purchased a new position in Medifast during the 4th quarter worth $2,952,000. Charles Schwab Investment Management Inc. raised its position in Medifast by 30.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock valued at $8,297,000 after purchasing an additional 181,618 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Medifast by 37.4% in the 2nd quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock worth $5,569,000 after buying an additional 107,854 shares during the period. Institutional investors own 95.51% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on MED. Weiss Ratings upgraded Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Zacks Research lowered Medifast from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $12.00.

Medifast News Summary

Here are the key news stories impacting Medifast this week:

• Positive Sentiment: Zacks raised its FY2026 EPS estimate to a loss of $1.04 from a loss of $1.97 and improved its Q3 and Q4 2026 forecasts to losses of $0.40 and $0.17 per share, respectively, versus prior estimates of $0.60 and $0.50.
• Positive Sentiment: Longer-term expectations also improved substantially. FY2027 EPS was revised to a loss of $0.47 from $1.89, while FY2028 EPS was revised to a loss of $0.43 from $1.81. These revisions point to a faster potential recovery in Medifast’s earnings.
• Positive Sentiment: Zacks also raised estimates for Q2 2027, Q3 2027, Q4 2027 and Q2 2028, with the largest revision moving Q4 2027 to a loss of $0.08 from $0.48.
• Neutral Sentiment: Despite the improved forecasts, Zacks maintained a Hold rating. The analyst’s current full-year consensus estimate remains a loss of approximately $1.00 per share, indicating that Medifast is still expected to report negative earnings in the near term.
• Negative Sentiment: The revised outlook still calls for losses through FY2028, limiting the fundamental support for a sustained rally. Medifast’s latest reported quarter also showed a net loss and negative margins, despite revenue and EPS exceeding analyst expectations.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.